Clinical Trials Logo

Blast Crisis clinical trials

View clinical trials related to Blast Crisis.

Filter by:

NCT ID: NCT00077467 Completed - Clinical trials for Recurrent Childhood Acute Lymphoblastic Leukemia

Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia

Start date: January 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of bortezomib in treating young patients with refractory or recurrent leukemia. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth.

NCT ID: NCT00077181 Completed - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies

Start date: January 2004
Phase: Phase 1
Study type: Interventional

Drugs used in chemotherapy, such as cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. 3-AP may help cytarabine kill more cancer cells by making them more sensitive to the drug. This phase I trial is studying the side effects and best dose of 3-AP when given with high-dose cytarabine in treating patients with advanced hematologic malignancies

NCT ID: NCT00068718 Completed - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

Start date: May 2003
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects of donor lymphocyte infusion and to see how well it works in treating patients with persistent, relapsed (disease that has returned), or progressing cancer after donor hematopoietic cell transplantation. White blood cells from donors may be able to kill cancer cells in patients with cancer that has come back (recurrent) after a donor hematopoietic cell transplant.

NCT ID: NCT00067028 Completed - Clinical trials for Acute Myeloid Leukemia

Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)

Start date: December 2003
Phase: Phase 2
Study type: Interventional

The goal is to compare the drug combinations clofarabine/idarubicin/ara-C, clofarabine/ara-C, and clofarabine/idarubicin in the treatment of patients with Acute Myeloid Leukemia, high-grade MDS, or myeloid blast phase of Chronic Myeloid Leukemia who have relapsed following their initial therapy.

NCT ID: NCT00054431 Completed - Clinical trials for Relapsing Chronic Myelogenous Leukemia

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

Start date: January 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving imatinib mesylate together with decitabine works in treating patients with accelerated or blast phase chronic myelogenous leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving imatinib mesylate together with decitabine may kill more cancer cells

NCT ID: NCT00053963 Completed - Clinical trials for Refractory Chronic Lymphocytic Leukemia

FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia

Start date: September 2002
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die

NCT ID: NCT00042003 Completed - Clinical trials for Chronic Myelogenous Leukemia

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Start date: July 2002
Phase: Phase 2
Study type: Interventional

To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia blastic phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.

NCT ID: NCT00034684 Completed - Leukemia Clinical Trials

Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)

Start date: July 2001
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, or Acute Lymphoblastic Leukemia.

NCT ID: NCT00025415 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

Start date: August 2001
Phase: Phase 1
Study type: Interventional

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have advanced cancer and liver dysfunction

NCT ID: NCT00015834 Completed - Clinical trials for Relapsing Chronic Myelogenous Leukemia

STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Start date: May 2001
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II trial to study the effectiveness of combining STI571 and chemotherapy in treating patients who have chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. STI571 may stop the growth of leukemia cells. Combining chemotherapy and STI571 may kill more cancer cells